Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Mar 6, 2020

Keywords

ClinConnect Summary

The Takayasu arteritis (TAK) is a rare chronic inflammatory arteritis, which lacks effective well-accepted intervention strategy. Previous studies have revealed that methoxamine, tofacitinib, adalimumab, and tocilizumab were effective in controlling disease activity and preventing disease relapse in some TAK patients. However, we believed that different patients should be prescribed different drug combinations, i.e. personalized medicine, to obtain the optimal intervention effect.

So, here we tried to classify the TAK patients into three levels, and prescribe different drug interventions t...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age≥14 years;
• • 2. active status: Kerr score≥ 2;
• 3. mild and moderate:
• • 1. Blood pressure (maximum) \< 180/110mmHg;
• • 2. 1-2 branches with the stenotic rate \< 70% involved;
• • 3. mildly ischemic manifestation relative to activity but relieve after rest;
• • 4. no or low degree of organ insufficiency: NYHF I\~II; eGFR (MRDR) ≥ 60ml/min;
• Exclusion Criteria:
• • 1. Severe organ insufficiency;
• • 2. Acute or chronic active infections including tuberculosis, hepatitis virus, etc.;
• • 3. Other autoimmune diseases including systemic lupus erythematosus, Behcet disease, IgG4 relative disease;
• • 4. malignant tumors;
• • 5. history of severe drug allergy;
• • 6. successive twice relapse occurs even after the intervention adjustment ( for the benefits of patients)